曲美布汀与多潘立酮治疗功能性消化不良30例临床疗效分析

目的 观察曲美布汀治疗功能性消化不良(FD)的临床疗效及安全性.方法 对我院收治的60例功能性消化不良患者随机分为治疗组和对照组,治疗组用曲美布汀100 mg,3次/d,口服;对照组用多潘立酮10 mg,3次/d,口服;所有患者疗程均为4周,观察两组治疗效果.结果 治疗组有效率90%,明显高于对照组73.3%(P<0.05),疗程结束时FD患者早饱、上腹胀痛、嗳气、食欲不振等症状治疗组明显改善,疗效优于对照组.治疗过程中两组均未发现明显的不良反应.结论 曲美布汀能明显缓解FD患者的症状,疗效优于多潘立酮,不良反应轻微,是治疗FD安全、有效的新一代胃肠动力药物.     

功能性消化不良的心理治疗分析

目的 研究功能性消化不良（FD）心理治疗的疗效.方法 选取180名确诊为FD的患者,随机分为治疗组（消化系统疾病常规治疗＋心理治疗）和对照组（消化系统疾病常规治疗）,治疗4周后计算有效率.结果 治疗组有效率为90.0%,显著高于对照组的68.9%（P＜0.05）.结论 心理疗法治疗功能性消化不良疗效满意,值得推广.     

康复新液联合莫沙必利治疗功能性消化不良的疗效观察

目的观察康复新液联合莫沙必利治疗功能性消化不良的疗效。方法将120例功能性消化不良患者随机分为治疗组(60例)和对照组(60例)。治疗组口服康复新液(每次10mL,1日3次,餐前半小时口服)联合莫沙必利(1次5mg,1日3次,餐前半小时口服);对照组口服莫沙必利,1次5mg,1日3次,于餐前半小时口服,疗程均为4周。结果治疗组临床有效率100%,对照组临床有效率81.7%,两组疗效比较差异有显著性(P<0.05)。治疗期间两组均无严重不良反应,不良反应发生率无显著性差异(P<0.05)。结论康复新液联合莫沙必利治疗功能性消化不良具有良好的临床效果,值得临床推广使用。     

兰索拉唑和阿莫西林配合伊托必利治疗功能性消化不良疗效观察

目的兰索拉唑和阿莫西林配合伊托必利治疗功能性消化不良疗效观察。方法将106例功能性消化不良患者,随机分成治疗组和对照组,每组各53例,治疗组口服兰索拉唑30mg/次,1次/d,每早空腹服;阿莫西林1000mg/次,3次/d,早中晚餐后服用;依托必利50mg/次,3次/d,早中晚餐后服用;疗程4周。对照组口服依托必利用法用量和疗程与治疗组相同。结果治愈率和总有效率治疗组在治疗功能性消化不良上均优于对照组。两组药物不良反应发生率无显著差异。结论治疗组在治疗功能性消化不良上均优于对照组,不良反应发生率无显著差异,值得临床推广。     

黛力新与西沙必利联合治疗功能性消化不良患者43例疗效观察

目的评价黛力新与西沙必利联合治疗功能性消化不良的疗效。方法随机将86例功能性消化不良患者分为治疗组和对照组,在心理干预的基础上,两组均给予西沙必利5mg,3次/d,餐前30min口服,治疗组加用黛力新1片,1次/d,晨服,疗程均为4周。结果治疗组有效率为88.4%,明显高于对照组;治疗组3个月的复发率为16.3%,明显低于对照组;两组比较差异均有显著性(P<0.01或P<0.05)。结论黛力新与西沙必利联合治疗功能性消化不良,疗效满意,用药安全,值得临床推广应用。     

帕罗西汀联合治疗功能性消化不良40例效果观察

目的探讨帕罗西汀辅助治疗功能性消化不良(FD)的效果。方法将40例FD随机分为观察组和对照组各20例,对照组予多潘立酮10 mg,每天3次口服,奥美拉唑20 mg,每天2次口服;观察组在对照组的基础上加用帕罗西汀10~20 mg,每天1次口服。2组均治疗4周,观察2组治疗效果。结果治疗组临床治愈率为45%,总有效率为95%;均高于对照组的临床治愈率30%,总有效率85%。2组临床治愈率和总有效率比较,差异有统计学意义(P<0.05)。结论常规治疗联合帕罗西汀治疗FD,效果良好,值得推荐。     

沙棘干乳剂配合穴位针刺治疗功能性消化不良的临床观察

目的观察沙棘干乳剂配合针刺治疗对功能性消化不良的临床疗效和安全性。方法将98例确诊为功能性消化不良的患者随机分为治疗组和对照组,治疗组50例,对照组48例。治疗组采用沙棘干乳剂25g/次,2次/日,针刺足三里、合谷、章门、内关、公孙、脐中四边穴,采用平补平泻手法,1次/日;对照组采用多潘立酮10mg/次,3次/日,共治疗2周,观察两组上腹疼痛、餐后不适等症状变化。结果治疗后两组患者症状均有改善,治疗组总有效率为98.0%,对照组总有效率为79.2%,治疗组显效和总有效率优于对照组(P<0.01),两组患者均无严重不良反应。结论沙棘干乳剂配合针刺治疗是治疗功能性消化不良有效、安全的方法。     

小剂量红霉素治疗小儿功能性消化不良33例疗效观察

目的探讨小剂量红霉素治疗小儿功能性消化不良的治疗效果。方法将66例功能性消化不良患儿随机分成治疗组33例和对照组33例,两组均在常规处理的同时,对照组予吗叮林每次0.3mg/kg,每日3次口服;治疗组给予红霉素口服,剂量为10mg/(kg.d),3次/日,两组疗程均为5天,对两组疗效进行评价。结果:治疗组总有效率90.90%;对照组总有效率60.60%,两组疗效差异有统计学意义,P<0.01。结论小剂量红霉素治疗小儿功能性消化不良具有良好的治疗效果。     

奥美拉唑联合莫沙必利治疗功能性消化不良患者的临床观察

目的：观察奥美拉唑联合莫沙必利治疗功能性消化不良的疗效。方法：选取我院82例功能性消化不良患者,随机分为两组：治疗组42人,给予奥美拉唑20毫克一日2次口服,联合莫沙必利5毫克一日3次口服。对照组40人,给予奥美拉唑20毫克,一日2次口服。两组用药4周,观察其治疗效果。结果：治疗组总有效率为83.33%,对照组总有效率为67.50%。两组对比疗效差异显著（P＜0.05）。结论：奥美拉唑联合莫沙必利治疗功能性消化不良疗效显著,值得在临床推广。     

多虑平与莫沙必利联合治疗功能性消化不良56例

目的观察多虑平（又名多塞平）联合莫沙必利治疗功能性消化不良的疗效影响。方法116例入选病人随机分为治疗组56例及对照组60例,治疗组口服多虑平12．5mg,每天2次;莫沙必利5mg,每天3次;对照组莫沙必利5mg,每天3次,治疗后1周、4周、3个月进行随防．观察疗效和复发率。结果治疗组第四周总有效率差异有显著性（P〈0．05）,随防3个月,复发率两组有显著性差异（P〈0．01）。结论应用多虑平联合莫沙必利治疗功能性消化不良可明显提高临床疗效。     

抗抑郁药曲唑酮治疗40例女性功能性消化不良病人

目的:观察曲唑酮治疗功能性消化不良(FD)的疗效。方法:40例女性FD病人予曲唑酮治疗6 wk(曲唑酮组),另外40例女性FD病人给予安慰剂治疗6 wk(安慰剂组)。用HAMD量表和水负荷试验对治疗前后FD病人和健康对照者(正常对照组)的精神状态和胃功能进行评估。同时对治疗前后病人腹胀、腹痛和早饱症状的缓解情况进行了评估。结果:曲唑酮组和安慰剂组治疗前HAMD评分分别为(23±s 5),(21±5)分,均高于正常对照组(3．8±2．8)分,均P<0．01;曲唑酮组和安慰剂组治疗前水负荷量分别为(918±164), (919±210)mL,均低于正常对照组(1 853±190)mL,均P<0．01;曲唑酮组治疗前后HAMD评分和水负荷量均有非常明显差异,均P<0．01;曲唑酮组和安慰组治疗前的症状积分为(6．5±1．4),(6．4±1．7)分,要明显高于治疗后(3．4±1．9),(5．6±1．7)分(P<0．01);曲唑酮组治疗后症状积分要明显低于安慰剂组(P<0．01);所有FD病人HAMD评分和水负荷量均呈负相关(均P<0．05)。结论:曲唑酮对FD病人的抑郁症状和胃容受性扩张功能都有明显改善,腹胀、腹痛和早饱症状也有一定缓解。     

盐酸伊托必利治疗功能性消化不良的临床研究

目的评价盐酸伊托必利治疗功能性消化不良(FD)的疗效及安全性。方法以多潘立酮为对照药,用随机、双盲双模拟、平行对照的试验方法,治疗FD病人42例,其中试验组21例,给予盐酸伊托必利50mg,每日3次;对照组21例,给予多潘立酮10mg,每日3次,疗程4周。治疗前后记录临床症状评分、检测胃排空功能、测定空腹血浆胃动素、胆囊收缩素水平。结果盐酸伊托必利可缓解FD患者的临床症状,改善胃排空功能,提高血浆胃动素水平,且无严重药物不良反应,疗效与多潘立酮相似。结论盐酸伊托必利可安全、有效地治疗FD,其疗效与提高血浆胃动素水平有关。     

多潘立酮联合香砂六君丸治疗功能性消化不良的临床观察

目的:观察多潘立酮联合香砂六君丸治疗功能性消化不良(FD)的临床疗效和安全性。方法:将106例FD的住院患者采用抽签方式随机均分为研究组和对照组。研究组患者口服多潘立酮片10 mg/次,tid,并口服香砂六君丸6 g/次,tid;对照组患者仅口服多潘立酮片10 mg/次,tid。两组患者均治疗4周。观察两组患者治疗前后的临床症状评分、总积分、临床疗效及不良反应发生情况。结果:治疗后,两组患者食欲不振、上腹不适、腹胀、餐后早饱、恶心呕吐、嗳气等临床症状评分均较治疗前显著下降,且研究组患者除上腹不适外,其他症状评分显著低于对照组,差异均有统计学意义(P<0.05),研究组患者临床症状总积分下降值和下降比例显著高于对照组,差异均有统计学意义(P<0.05);研究组患者总有效率显著高于对照组,差异有统计学意义(P<0.05);两组患者均未见明显不良反应发生。结论:多潘立酮联合香砂六君丸治疗FD的疗效显著优于单用多潘立酮,且安全性较好。     

Pharmacokinetics of Trazodone During Multiple Dosing to Psychiatric Patients

Abstract: Steady-state pharmacokinetics of trazodone were investigated over a period of 4 weeks in seven psychiatric patients after repeated oral administrations of 50, 100, and 150 mg twice daily for one, one, and two consecutive weeks, respectively. Unchanged trazodone was determined by high performance liquid chromatography after a basic extraction. A steady-state level of serum trazodone was achieved for the 50 mg dose within 36 hr, while a new steady state level after increasing the dose to 100 mg and then 150 mg twice daily apparently was achieved at 12 hr. Trazodone showed linear pharmacokinetics within the dosage range investigated. The following main parameters were calculated at steady state for psychiatric patients (mean±S.D.): t_1/2 = 7.0±1.2, V_β/F = 0.50±0.131/kg and Cl_t/F = 3.2±0.51/hr. These pharmacokinetic parameters did not differ significantly from those earlier reported in healthy subjects after a single dose administration of 100 mg when based on an oral availability of trazodone of 65%.     

盐酸伊托必利治疗功能性消化不良的多中心临床研究

目的：观察盐酸伊托必利(商品名：瑞复啉)治疗功能性消化不良的疗效和安全性。方法：本多中心临床试验采用随机双盲平行对照方法，以多潘立酮作为对照。80例功能性消化不良患者被随机分成试验组和对照组。2组均为40例，试验组给盐酸伊托必利50mg，po，tid；对照组给多潘立酮10mg，po，tid。疗程均为2周。结果：2组患者功能性消化不良的症状均显著缓解，疗效相近，但餐后饱胀的改善作用试验组优于对照组。结论：盐酸伊托必利是治疗功能性消化不良有效而安全的新一代促胃肠动力药物。     

Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study

Objective To evaluate the potential role of tegaserod in the management of functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) in patients with chronic constipation and to determine the possible efficacy of tegaserod on solid-phase gastric emptying and gastric hypersensitivity. Method This was an exploratory open-label trial of tegaserod therapy for dyspepsia and reflux symptoms in patients with chronic constipation. The study cohort consisted of 90 patients randomized to three treatment groups for a study period of 4 weeks (tegaserod 6 mg, twice daily; esomeprazole 40 mg, once daily; tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily). Twenty healthy volunteers provided control values. Clinical symptoms were evaluated by one of the investigators using a Gastrointestinal Symptom Rating Scale (GSRS). Solid-phase gastric emptying and colonic transit were measured by the radiopaque barium marker method, and the water load test (WLT) was used to evaluate gastric sensation and the function of proximal stomach. The proportions of patients with complete relief of epigastric pain /discomfort, epigastric fullness, early satiety and heartburn in the tegaserod group and the tegaserod plus esomeprazole group were compared with the esomeprazole group, respectively. Results The mean global gastrointestinal (GI) scores of all three treatment groups reported using the GSRS showed the same trend, with decreasing scores over the 4-week study period indicating a reported decreasing severity of symptoms that was significantly different from baseline values. Patients in the tegaserod plus esomeprazole group reported the lowest global GI scores after 4 weeks, as expected. Solid-phase gastric emptying (GER) and colonic transit (CTT) increased significantly in the tegaserod 6 mg twice daily group compared with baseline. These parameters did not change in the esomeprazole group at week 4 compared with baseline. In terms of gastric sensation, in the tegaserod group, the proportions of patients with hypersensitivity of the first perception threshold did not change at week 2 or week 4 compared with baseline; however, in this group and in the tegaserod plus esomeprazole group, the proportions of patients with hypersensitivity of discomfort threshold decreased significantly at week 4 compared with baseline. In the esomeprazole group, there were no changes in the proportions of patients with hypersensitivity of the first perception threshold and discomfort threshold at week 2 or 4 compared with baseline. No severe adverse events were recorded, and the medications were in general well-tolerated. Conclusion Tegaserod is effective and safe at improving dyspepsia and reflux symptoms in patients with chronic constipation, and tegaserod plus esomeprazole is superior to esomeprazole alone in the resolution of epigastric pain/discomfort and heartburn.     

盐酸曲唑酮提高雄性大鼠血清中一氧化氮水平的作用研究

目的:研究盐酸曲唑酮提高♂大鼠血清一氧化氮(NO)水平的作用,并探讨其与改善临床勃起功能障碍(ED)的相关性。方法:将50只♂大鼠随机分为5组,每组10只,分别为正常对照组,盐酸曲唑酮低、中、高(21、42、84mg/(kg.d))剂量组,万艾可阳性对照组;正常对照组用生理盐水灌胃,药物组将药物用注射用水调成糊状灌胃,每次给药量为0.5ml/100g,正常对照组及药物组均为3次/d,连续3d;阳性对照组按46.5mg/kg于取样当日给药2次。按NO试剂盒要求,对大鼠断头取血,测试血中NO水平。结果:盐酸曲唑酮低、中、高剂量组大鼠血清的NO水平均明显升高,3组和阳性对照组与正常对照组比较均有显著性差异(P<0.01);盐酸曲唑酮中、高剂量组与阳性对照组比较有显著性差异(P<0.01),低剂量组与阳性对照组比较则无显著性差异(P>0.05)。结论:盐酸曲唑酮可显著提高♂大鼠血清NO水平,其可改善ED的机制与促进NO释放有相关性。     

Protective effects of water‐soluble low‐molecular‐weight β‐(1,3‐1,6)D‐glucan purified from Aureobasidium pullulans GM‐NH‐1A1 against UFT toxicity in mice

Objectives 5‐Fluorouracil and its derivatives are widely used in the treatment of a variety of tumours. However, their use is associated with gastrointestinal toxicity, myelotoxicity and immune toxicity. In this study, we examined the protective effects of low‐molecular‐weight β‐glucan isolated from Aureobasidium pullulans GM‐NH‐1A1 against toxicity of UFT (combination of tegafur (1‐(2‐tetrahydrofuryl)‐5‐fluorouracil) and uracil) in mice bearing colon 26 tumours. Methods UFT was administered orally at 50 mg/kg once daily for 14 days alone or with orally administered low‐molecular‐weight β‐glucan, 25, 50 and 100 mg/kg twice daily. Key findings Tumour growth was inhibited equally in all treatment groups. Onset of diarrhoea, which started on day 9 of UFT administration, was delayed by concomitant administration of the β‐glucan (50 and 100 mg/kg twice daily). Histological analysis showed that damage to small‐intestine villi by UFT was inhibited by the orally administered β‐glucan. Conclusions Oral administration of low‐molecular‐weight β‐glucan prevents gastrointestinal mucositis associated with UFT therapy without interfering with its anti‐tumour activity.     

Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia

AIM: To assess the efficacy and safety of enteric coated capsules containing a fixed combination of 90 mg peppermint oil and 50 mg caraway oil (PCC; Enteroplant) in patients with functional dyspepsia. METHODS: A total of 96 out-patients received one capsule twice daily of PCC or placebo for 28 days. Primary efficacy variables were the intra-individual change in (i) pain intensity and (ii) sensation of pressure, heaviness and fullness between days 1 and 29, and the investigators' rating of (iii) global improvement (Clinical Global Impressions [CGI] item 2) on day 29. A global type I error of alpha=0.05 was controlled by a priori ordering of hypotheses. RESULTS: All patients were evaluable for efficacy and safety. On day 29, the average intensity of pain was reduced by 40% vs. baseline in the PCC group and by 22% in the placebo group. With regards to pressure, heaviness and fullness, a 43% reduction was observed for PCC vs. 22% for placebo. In CGI item 2, 67% (PCC) vs. 21% (placebo) of the patients were described as much or very much improved. In all three target parameters, the superiority of PCC over placebo was statistically significant. Six patients (PCC: 5; placebo: 1) reported adverse events, either unrelated to the trial, or attributable to an aggravation of the disease under investigation. Eructation with peppermint taste did not occur. CONCLUSION: These results demonstrate the good tolerability and the favourable risk-benefit ratio of PCC for the treatment of functional dyspepsia.